Skip to main content

Advertisement

Log in

Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

PURPOSE: This study is designed to describe colonic histology in patients with primary sclerosing cholangitis (PSC) without clinical symptoms of inflammatory bowel disease (IBD) and to do a follow-up study of these patients to find the time span from first detection of histologic signs until development of clinical symptoms of IBD. METHODS: In a cohort of 76 patients with PSC treated at Huddinge University Hospital, 11 patients did not have any clinical symptoms of IBD at the time of PSC diagnosis. Nine of these patients underwent diagnostic colonoscopy with multiple biopsies. RESULTS: In the group of nine PSC patients, without clinical signs of IBD undergoing colonoscopy, histologic signs of IBD were found in seven patients (6 ulcerative colitis and 1 Crohn's disease). Among them one had dysplasia, and another had epithelial changes probably positive for dysplasia. Two other patients had histologic signs of inflammation, however, not fully compatible with IBD. Three of 11 patients developed clinical symptoms of IBD after one, three, and seven years of follow-up since diagnostic colonoscopy. CONCLUSIONS: In patients with PSC, histologic signs of IBD, including premalignant changes, may precede development of clinical symptoms of IBD by as much as seven years. This indicates that IBD onset may have a substantial subclinical phase of IBD far longer than previously appreciated. This finding may be of clinical importance because underestimation of disease duration may delay inclusion of PSC patients with extensive colitis in colonoscopic surveillance programs. The subclinical phase may also allow the studies of early pathogenesisin vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Foster DW. Harrison's principles of internal medicine. 12th ed. New York: McGraw-Hill, 1991:1739–42.

    Google Scholar 

  2. Atkinson MS, Maclaren NK. What causes diabetes? Sci Am 1990;263:42–9.

    Article  Google Scholar 

  3. Aadland E, Schrumpf E, Fausa O,et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987;22:655–64.

    PubMed  CAS  Google Scholar 

  4. McGarity B, Bansi DS, Robertsson DA, Millward-Sadler GH, Shepherd HA. Primary sclerosing cholangitis: an important and prevalent complication of Crohn's disease. Eur J Gastroenterol Hepatol 1991;3:361–4.

    Google Scholar 

  5. Chapman RW, Arborgh BA, Rhodes JM,et al. Primary sclerosing cholangitis; a review of its clinical features, cholangiography and hepatic histology. Gut 1980;21:870–7.

    PubMed  CAS  Google Scholar 

  6. Wiesner RH, La Russo NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;79:200–6.

    PubMed  CAS  Google Scholar 

  7. Broberger O, Perlman P. Autoantibodies in human ulcerative colitis. J Exp Med 1959;110:657–74.

    Article  PubMed  CAS  Google Scholar 

  8. Duerr RH, Targan SR, Landers CJ,et al. Neutrophil cytoplasmic autoantibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991;1001:1385–91.

    Google Scholar 

  9. Selby WS, Janossy G, Boffil M, Jewell DP. Intestinal subpopulations in inflammatory bowel disease: an analysis by immunhistochemical and cell isolation technique. Gut 1984;32:779–83.

    Google Scholar 

  10. Senju M, Wu KC, Mahida YR, Jewell DP. Two colour immunofluoroscence and flow cytometric analysis of lamina propria lymphocytes subsets in ulcerative colitis and Crohn's disease. Dig Dis Sci 1991;36:1453–8.

    Article  PubMed  CAS  Google Scholar 

  11. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31–9.

    Article  PubMed  CAS  Google Scholar 

  12. Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease: a study of sixty-six subjects. Hepatology 1990;11:7–11.

    PubMed  CAS  Google Scholar 

  13. Broomé U, Lindberg G, Löfberg R. Primary sclerosing cholangitis in ulcerative colitis-a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102:1877–80.

    PubMed  Google Scholar 

  14. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993;88:1174–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by grants from the Nanna Svartz Scholarship.

About this article

Cite this article

Broomé, U., Löfberg, R., Lundqvist, K. et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum 38, 1301–1305 (1995). https://doi.org/10.1007/BF02049156

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02049156

Key words

Navigation